Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

What's next?

Machen Sie mit BB Biotech zukunftsweisende Medikamente zu Ihrer gewinnbringenden Wertanlage – dank eines internationalen Experten-Teams aus Finanz und Wissenschaft mit erfolgreichem Track-Record.

Warum in die Biotechnologie investieren?

  • Wachstumsindustrie

  • Welt im Wandel

  • Excellence

  • 30 Jahre Erfahrung

  • Gut diversifiziert

  • Attraktive Dividende

What’s next? BB Biotech in Kürze 

Meilensteine der Biotechnologie

Renditerechner BB Biotech

gute Entwicklungmoderate Entwicklungschlechte Entwicklung
Rechtlicher Hinweis

Die dargestellten Szenarien sind simulierte Wertentwicklungen, die auf der historischen, rollierenden 1-, 3-, 5- und 10-Jahres-Performance der BB Biotech seit der Lancierung vor 30 Jahren beruhen (Total-Return-Methodologie in CHF nach Abzug der Verwaltungsgebühr, allerdings ohne individuelle Zusatzkosten wie z.B. Depotgebühren und Transaktionskosten). Der Rechner verwendet vergangene Performancedaten, wobei das 80. Perzentil* für die gute Wertentwicklung, der Median für die moderate Wertentwicklung und das 20. Perzentil** für die schlechte Wertentwicklung verwendet wird.

Schlechte Wertentwicklung über 10 Jahre: +83.1%. Dieses Szenario ereignete sich zwischen 11/2002 und 11/2012
Moderate Wertentwicklung über 10 Jahre: +224.4%. Dieses Szenario ereignete sich zwischen 7/2004 und 07/2014
Gute Wertentwicklung über 10 Jahre: +512.7%. Dieses Szenario ereignete sich zwischen 05/2008 und 05/2018

Die Wertentwicklung in der Vergangenheit lässt keine Rückschlüsse auf die zukünftige Entwicklung zu und kann irreführend sein. Zukünftige Marktentwicklungen können nicht genau vorhergesagt werden. Die gezeigten Szenarien sind nur ein Hinweis basierend auf den historische Renditen. Die tatsächlichen Renditen könnten niedriger ausfallen.

*80% Perzentil bedeutet: In 20% der Fälle hätte sich die Anlage besser entwickelt.
**20% Perzentil bedeutet: In 80% der Fälle hätte sich die Anlage besser entwickelt.

  • Dividendenpolitik

    Dividendenpolitik

    Wachstumstitel mit Dividendenrendite

    Werte mit hoher Dividendenrendite sind in der Regel eher in defensiven Sektoren mit geringerem Kurssteigerungspotenzial zu finden. Nicht so bei BB Biotech. Die Beteiligungsgesellschaft vereint hohes Wachstum mit einer substanziellen Dividendenrendite. 

10 grösste Portfoliopositionen

Podcast

Entdecken Sie eine der Schlüsseltechnologien des 21. Jahrhunderts: die Biotechnologie. Erfahren Sie von führenden Experten in unserem Podcast «What’s next» mehr über  die zukunftsweisenden medizinischen Möglichkeiten dieser faszinierenden Branche und wie Sie als Anleger davon profieren können. Seien Sie dabei, wenn BB Biotech die Zukunft mitgestaltet.
Listen on Spotify Badge
  • What's next, Can Buldun?

    Wie KI die Medikamentenentwicklung vorantreibt und BB Biotech bei Investitionsentscheidungen unterstützt.

    Dr. Can Buldun, Data Scientist im Investment Management Team BB Biotech

  • What's next, Daniel Koller?

    Über das Potenzial neuer biotechnologischer Möglichkeiten in der Medizin.

    Dr. Daniel Koller, Head Investment Management Team BB Biotech

What's next, Can Buldun?

Wie KI die Medikamentenentwicklung vorantreibt und BB Biotech bei Investitionsentscheidungen unterstützt.

Dr. Can Buldun, Data Scientist im Investment Management Team BB Biotech

What's next, Daniel Koller?

Über das Potenzial neuer biotechnologischer Möglichkeiten in der Medizin.

Dr. Daniel Koller, Head Investment Management Team BB Biotech

What's next, Daniel Koller?

  • Interview

    Warum die Biotechnologie zu den Schlüsseltechnologien des 21. Jahrhunderts gehört, welche Biotechfirmen und Therapiegebiete BB Biotech im Fokus hat und was Künstliche Intelligenz damit zu tun hat, dazu äussert sich Daniel Koller, Head Investment Management Team BB Biotech.

Bleiben Sie am Puls

Melden Sie sich hier für unseren Newsletter an.

*indicates required fields.
We respect your privacy and do not sell, rent or loan any identifiable information collected on this site. Any information that you give us will be treated with the utmost care and security. It will not be used in ways to which you have not consented.
  • Überall und jederzeit Zugriff auf Daten rund um BB Biotech und den Biotechsektor. 

Insights